Suchergebnisse - "Goldman, Jonathan W"

PubPharm (136)

31

A plain language summary of results from the ADAURA study : osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer

enthalten in: Future oncology (London, England) | 2021

von Wu, Y. | Tsuboi, M. | John, T. | +20

CommentOn: N Engl J Med. 2020 Oct 29;383(18):1711-1723. - PMID 32955177

32

Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Zhou, N. | Velez, M. | Bachrach, B. | +14

33

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

enthalten in: Clinical lung cancer | 2021

von Yu, H. | Goldberg, S. | Le, X. | +17

34

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Camidge, D. | Morgensztern, D. | Heist, R. | +14

35

The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

enthalten in: Expert review of anticancer therapy | 2021

von Jhaveri, K. | Burris Rd, H. | Yap, T. | +8

36

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Shafique, M. | Fisher, T. | Evans, E. | +18

37

Combination treatment options for small-cell lung cancer - Authors' reply

enthalten in: The Lancet. Oncology | 2021

von Goldman, J. | Paz-Ares, L.

CommentOn: Lancet Oncol. 2021 Jan;22(1):51-65. - PMID 33285097

38

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer

enthalten in: Clinical and translational science | 2021

von Goldman, J. | Barve, M. | Patel, J. | +12

39

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : updated results from a randomised, controlled, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Goldman, J. | Dvorkin, M. | Chen, Y. | +123

CommentIn: Lancet Oncol. 2021 Mar;22(3):e83. - PMID 33662291

40

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer

enthalten in: Clinical and Translational Science | 2021

von Goldman, J. | Barve, M. | Patel, J. | +12